Goutham Sunny: Immunotherapy in MSI-H Gastric Cancer – NO LIMIT trial
Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, posted on X:
“Immunotherapy in MSI-H Gastric Cancer – NO LIMIT trial.
Phase II trial: 1st-line Nivolumab + low-dose Ipilimumab in MSI-H AGC (5–6% of AGC) – 29 patients, NIVO q2w + IPI q6w.
Results:
- ORR: 62.1%
- CR: 10.3%
- DCR: 79.3%
- Median PFS: 13.8 mo
- Median OS: NR (12-mo OS: 79.5%)
- TRAEs in 93.1% (≥G3: 37.9%)
- 41% discontinued due to AEs
But 11/12 had durable benefit post-discontinuation.”
Title: Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer
Authors: Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Kazuhiro Kakimi, Yasutaka Chiba, Narikazu Boku, Ichinosuke Hyodo, Kei Muro
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Goutham Sunny.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023